Related Experiment Video
Updated: Aug 16, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Cardiac toxicity with thioridazine-tricyclic antidepressant combination
Combining thioridazine with tricyclic antidepressants can cause dangerous heart rhythm problems. This combination, often used for depression, poses a significant risk of life-threatening ventricular arrhythmias.
Area of Science:
- Cardiology
- Psychopharmacology
- Clinical Toxicology
Background:
- Thioridazine and tricyclic antidepressants (TCAs) are commonly prescribed, sometimes in combination for treating depression with anxious and retarded features.
- Both thioridazine and TCAs are known to adversely affect cardiac repolarization, potentially increasing cardiovascular risks.
Observation:
- Two cases are presented involving patients who ingested both thioridazine and TCAs.
- These patients developed severe cardiac complications.
Findings:
- The co-ingestion of thioridazine and TCAs was associated with life-threatening ventricular arrhythmias.
- This highlights a significant pharmacodynamic interaction with potentially fatal consequences.
Implications:
- Clinicians should exercise extreme caution when prescribing thioridazine and TCAs concurrently.
- Awareness of this drug combination's cardiotoxic potential is crucial for patient safety and risk management in psychiatric pharmacotherapy.
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Drug–Drug Interaction

